Van Rein, N., Heide-Jorgensen, U., Lijfering, W.M., Dekkers, O.M., Sorensen, H.T. and Cannegieter, S.C. (2019) Major Bleeding Rates in Atrial Fibrillation Patients on Single, Dual and Tiple Antithrombotic Therapy. Results from a National Danish Cohort Study. Circulation, 139, 775-786.
https://doi.org/10.1161/CIRCULATIONAHA.118.036248

has been cited by the following article:

• TITLE: Historical Evolution of the Anticoagulant-Antiplatelet Therapy in Patients with Mitral Valve Disease Associated to Atrial Fibrillation or Mechanical Valve Prosthesis. Role of Omeprazole

  AUTHORS: Francisco Perez Gómez, Ramon Bover

  KEYWORDS: Ischemic Heart Disease, Anticoagulant-Antiplatelet Therapy

  JOURNAL NAME: World Journal of Cardiovascular Diseases, Vol.10 No.10, October 22, 2020

  ABSTRACT: In this review article we analyze the historical evolution of anticoagulant and antiplatelet therapies in the treatment of atrial fibrillation plus complicated heart diseases. Its combined use, compared with anticoagulation alone, has been widely used to significantly reduce thromboembolic risk. Major bleeding risk has been usually registered during combined antithrombotic therapy, which is mainly due to gastric bleeding, but enteric coating antiplatelet tablets can effectively protect against gastric mucosal damage, and the addition of proton-pump inhibitors (omeprazole) can avoid it.